注射用黄芪多糖联合静脉热化疗治疗晚期非小细胞肺癌临床疗效观察

目的:观察注射用黄芪多糖联合静脉热化疗治疗晚期非小细胞癌近期疗效、临床受益反应及不良反应。方法:2008年7月-2011年4月收治晚期非小细胞癌肺患者95例,随机分为为注射用黄芪多糖联合静脉热化疗组(观察组)47例,静脉热化疗组48例(对照组),均采用NP方案(盖诺+顺铂)化疗联合深部热疗,观察组加用注射用黄芪多糖。观察两组患者的近期疗效、临床受益反应及不良反应。结果:治疗组有效25例(44.7%),对照组有效15例(31.3%)。治疗组有效率高于单纯化疗组(χ2=4.69,P0.05);治疗组出现CBR 20例(42.6%),对照组出现CBR13例(27.1%),两组CBR出现率的差异有统计学意义(χ2=8.98,P0.05)。两组白细胞减少、胃肠道反应、肝功能损害等不良反应发生率的差异显著,有统计学意义(P0.05)。结论:黄芪多糖联合静脉热化疗治疗晚非小细胞肺癌可显著提高热化疗患者的临床疗效,减少热化疗期间不良反应,改善患者生活质量。

Clinical Observation of Astraglaus Polysaccharide Combined with Thermo-Chemotherapy in Patients with Non-Small Cell Lung Cancer

Objective:To observe the therapeutic effect and safety of Astraglaus polysaccharide combined with thermo-chemotherapy in patients with non-small cell lung cancer.Methods:95 patients with non-small cell lung cancer cancer were divided into 2 groups:47 patients received Astraglaus polysaccharide with thermo-chemotherapy(therapy group),48 patients were treated with thermo-chemotherapy alone(control group).NVB and cisplatin(DDP)were adopted for 2 cycles,combing with Astraglaus polysaccharide injection in the treated group.Results:In the treated group,the overall response rate(CR and PR)was 44.7%,while that in control group was 31.3%(P<0.05).The clinical benefit response rate of treated group was significantly higher than that of control group(42.6% vs 27.1%,P<0.05).There were significant differences between two groups in toxicities of myelosuppression,gastrointestinal tract and liver(P<0.05).Conclusion:Astraglaus polysaccharide combined with thermo-chemotherapy is effective and safe for patients with non-small cell lung cancer.